

สถิติโรคมะเร็ง โรงพยาบาลมะเร็งลำปาง ปี พ.ศ. 2566 (Hospital-Based Cancer Registry Annual Report 2023)



Cancer Registry Unit,
Lampang Cancer Hospital

June 2024

ISBN: 978-616-8322-75-8

Foreword



"Lampang Cancer Hospital (LPCH), which is under the Department of Medical Services, Ministry of Public Health, provides cancer diagnosis and treatment services, including cancer registration, covering the northern region. The number of new cancer patients has been continuously increasing. Our hospital is committed to maintaining quality and service standards to ensure a good quality of life for cancer patients.

The changes in social conditions and technology and the current outbreak of emerging diseases. LPCH has adjusted the hospital's strategic plan, from 2023 to 2027, focusing on the vision of becoming a high-performance cancer hospital in terms of technology and medical innovation, aiming to improve people's quality of life. The plan also focuses on academic development, knowledge transfer, and providing cancer care services through network partners.

In 2023, LPCH received the Excellent level in OAP award, Radiation Generator Type 2 (Medical). In addition, LPCH passed the 4th hospital standard certification (Re-Accreditation survey 4th), passed the Challenge level assessment in the Green and Clean Hospital Challenge, and passed the Moderate level in the Government Easy Contact Center (GECC).

Furthermore, LPCH has been supporting the operations of Health Regions 1 and 2 in terms of academic support, treatment, and referrals for cancer patients in the northern region. As a result, the health regions have shown good performance. These successful outcomes are a result of the cooperation between the hospital's management team and personnel. LPCH continues to strive towards improving the quality of cancer care in all aspects, aiming to enhance the quality of life for all Thai people."

P. Kooprasertying
(Dr. Pipat Kooprasertying)

Acting Director of Lampang Cancer Hospital

Hospital-Based Cancer Registry 2023
Lampang Cancer Hospital



Preface

The hospital-based cancer registration (HBCR) is a part of the cancer information system. The Ministry of Public Health has a policy for A, S, and M1-level hospitals to establish cancer registration and report HBCR as well. This policy facilitates a national cancer registry and annual cancer statistics report in Thailand.

Lampang Cancer Hospital (LPCH) has an HBCR under the responsibility of the cancer registry unit, which started in 2000. The focus of the registry is on collecting quality data according to international standards, ensuring accuracy and reliability. Notably, in 2022, all staff members of the cancer registry unit obtained "Professional ICD-O Coding" certificates from Mahidol University in Thailand. This demonstrates LPCH's commitment to maintaining a robust cancer registry system.

This cancer statistics annual report for 2023 is a report from the HBCR cancer registry. This HBCR report issue No. 24 presents the statistics of new cancer patients who received services at LPCH between January 1st and December 31st, 2023. The report provides an overview and separates the data by the seven most common cancers.

This annual report is a product of the collaborative efforts of the LPCH cancer registry unit and the entire LPCH staff. We are grateful to the senior executive team for their continued support of the HBCR. We hope this report will be instrumental in planning the operation, support, and development of LPCH, while also providing valuable information to those interested in LPCH's cancer care services.

Cancer registry Unit
Lampang Cancer Hospital

Contents

Foreword	I
Preface	II
Faculty of providers	IV
Cancer diagnosis and treatment tools, Lampang Cancer Hospital	V
Process for Cancer Registry data collection	VII
Data visualization	VIII
Overview of new cancer patients in Lampang Cancer Hospital	1
10 Leading new cancer patients in Lampang Cancer Hospital by Sex	6
10 Leading new cancer patients in Lampang Cancer Hospital (Both Sex)	7
7 Common Cancers in Lampang Cancer Hospital	8
(1) Head and Neck Cancer	9
(2) Colorectal Cancer	12
(3) Liver and bile duct Cancer	15
(4) Trachea, Bronchus, and lung Cancer	18
(5) Breast Cancer	21
(6) Cervical Cancer	25
(7) Thyroid Cancer	29
Number of new cancer by age and sex in Lampang Cancer Hospital (Male)	32
Number of new cancer by age and sex in Lampang Cancer Hospital (Female)	33
Pathology according to site and sex	34
Productivity of Cancer Registry, Lampang Cancer Hospital	41

Functional structure Cancer registry unit, LPCH

Advisory group



Dr. Pipat Kooprasertying
Acting Director
of Lampang Cancer Hospital



Dr. Tawarat Ruanrojrun
Deputy Director for Health System
Development



Mrs. Sureerat Phuangsaibai
Deputy Director of Nursing



Mrs. Arada Pawong
Medical Statistics Technician
Head of Digital Medical Department
Head of Medical Records and Statistics

Staff



Mrs. Karnchana Daoprasert
Registered Nurse
Head of cancer registry unit



Ms. Ratchaneewan Chansawang
Registered Nurse



Mrs. Kanniga Suksai
Registered Nurse



Mrs. Sirinya Mahawat
Statistician



Ms. Monthitinun Praditkay
Statistician



Ms. Ketsiri Khamkhod
Statistician




Mr. Weerapun Thongdee
Medical Statistics Technician



Mrs. Panida Suwanamuang
General Service Officer

Contact:  <https://www.lpch.go.th/canreg/>

 lampangregistry@gmail.com

 054-335262-8 ต่อ 113

Medical Equipment for Cancer diagnosis and treatment, Lampang Cancer Hospital

Radiotherapy

- 2012, Intensity Modulated Radiation Therapy Treatment Planning (IMRT Planning).
- 2013, Quality Assurance and Intra Treatment Verification.
- 2013, Linear Accelerator with Multi-Leaf Collimator (started using January 2014).
- 2016, Three Dimension for Intensity Moderated Radiotherapy Treatment Planning and Atlas-Based Organ Delineation lesion drawing program.
- 2017, The device determines the position and shape of the lesion and adjacent normal organs with a program to analyze changes in lesion size and normal organs between radiation therapy.
- 2017, High Energy Linear Accelerator with six degrees of freedom couch for SBRT and radiation oncology information system.
- 2018, Patient QA for Pre-Treatment QA.
- 2019, High Dose rate Control after loading with cobalt-60; 25 channel.
- 2019, High Energy Linear Accelerator with Image Guide.
- 2022, Superficial Hyperthermia.
- 2023, 4D Computed tomography simulator.



Volumetric Modulated
Arc therapy (VMAT)



Intensity Modulated Radiotherapy
Linear Accelerator

Medical Equipment for Cancer diagnosis and treatment, Lampang Cancer Hospital

Diagnostic Radiology

- 2010, Aplio MX Ultrasound
- 2013, Digital Subtraction/Flat Panel Detector; Model ZEXIRA
- 2016, Digital General x-ray
- 2016, Digital Mobile X-ray; Model SM-20HF-B-D-C
- 2018, Selenia Dimensions Digital Mammogram 2D and 3D
- 2019, Aplio i600 Ultrasound
- 2021, LOGIQ E10 Ultrasound
- 2021, Picture Archiving and Communication System and Radiology Information System (PACS & RIS)
- 2022, Aquilion Prime SP 160 Slice CT scanner
- 2023, Aplio i700 Prism Ultrasound


Nuclear Medicine

- 2016, Bone densitometer
- 2017, Thyroid uptake
- 2018, Single Photon Emission Computed Tomography/CT; SPECT/CT
- 2023, single Photon Emission Computed Tomography/CT: SPECT/CT




Single Photon Emission Computed Tomography/CT; SPECT/CT

Process for Hospital-Based Cancer Registry data collection




Hospital-Based Cancer




Top 5 Leading Cancer

Male



1. Colorectal
2. Prostate
3. Lung
4. Pharynx
5. Liver and bile duct

Female




1. Breast
2. Cervix uteri
3. Lung
4. Colorectal
5. Thyroid

Cancer Registry 2023

1

91.1%

of the patients live in
health region 1



2

7.3%

of the patients live in
health region 2



Type of Diagnosis

94% Histological proof

- ✓ Histology of primary
- ✓ Histology of metastasis
- ✓ Cytology and hematology

6% No histological proof

- ✓ Clinical investigation
- ✓ Surgery without histology




Treatment

- ✓ Radiotherapy 44.7%
- ✓ Concurrent RT 19.6%
- ✓ Systemic therapy 9.8%
 - Chemotherapy 9.0%
 - Targeted therapy 1.4%
 - Immunotherapy 0.1%
- ✓ Palliative care 13.9%
- ✓ I-131 3.5%
- ✓ Surgery 1.9%
- ✓ Hormone 0.5%
- ✓ Consult/Investigation 27.7%

Note: Investigation = CT/Bone
Scan/Ultrasound/Mammogram/Total body scan

New cancer patients in Lampang Cancer Hospital, 2023


All new cancer patients undergoing service in Lampang Cancer Hospital in 2023 have 2,902 cases (25.2% of all new cases and 3.5% of all outpatients). In addition, the number of new cancer patients in 2023 increased from 2014 by 31.8%



Cases	Number	Percentage (%)
Number of all outpatients	82,943	100.0
Number of all new cases (Checkup, cancer cases and other disease)	11,530	13.9
Number of new cancer cases	2,902	3.5 (of all outpatients) 25.2 (of all new cases)


New cancer patients in Lampang Cancer Hospital by age and sex, 2023

Age group (Year)	Male		Female		Both sex	
	N	%	N	%	N	%
0 - 4	0	0.0	1	0.0	1	0.0
5 - 9	0	0.0	0	0.0	0	0.0
10 - 14	1	0.1	1	0.0	2	0.1
15 - 19	7	0.2	6	0.2	13	0.4
20 - 24	7	0.2	15	0.5	22	0.7
25 - 29	11	0.4	22	0.8	33	1.2
30 - 34	6	0.2	52	1.8	58	2.0
35 - 39	18	0.6	80	2.8	98	3.4
40 - 44	25	0.9	134	4.6	159	5.5
45 - 49	47	1.6	172	5.9	219	7.5
50 - 54	91	3.2	230	7.9	321	11.1
55 - 59	132	4.5	315	10.9	447	15.4
60 - 64	220	7.6	286	9.9	506	17.5
65 - 69	242	8.3	228	7.9	470	16.2
70 - 74	153	5.3	134	4.6	287	9.9
75 - 79	92	3.2	76	2.6	168	5.8
80 - 84	42	1.4	27	0.9	69	2.3
85 +	18	0.6	11	0.4	29	1.0
Total	1,112	38.2	1,790	61.7	2,902	100.0



Location of new cancer patients in Lampang Cancer Hospital, 2023


Provinces	Male		Female		Total	
	N	%	N	%	N	%
Chiang Rai	269	9.27	486	16.75	755	26.02
Lampang	293	10.10	409	14.10	702	24.20
Phrae	154	5.30	201	6.93	355	12.23
Phayao	114	3.93	195	6.72	309	10.65
Chiang Mai	73	2.52	162	5.58	235	8.10
Nan	77	2.65	122	4.21	199	6.86
Uttaradit	51	1.76	57	1.97	108	3.73
Lamphun	16	0.55	54	1.87	70	2.42
Tak	23	0.79	32	1.11	55	1.90
Sukhothai	27	0.93	18	0.63	45	1.56
Kamphaeng Phet	4	0.14	20	0.69	24	0.83
Mae Hong Son	2	0.07	18	0.62	20	0.69
Phitsanulok	0	0.00	4	0.14	4	0.14
Kanchanaburi	2	0.07	1	0.03	3	0.10
Khon Kaen	0	0.00	1	0.03	1	0.03
Chon Buri	0	0.00	1	0.03	1	0.03
Nakhon Pathom	1	0.03	0	0.00	1	0.03
Nakhon Phanom	1	0.03	0	0.00	1	0.03
Nakhon Ratchasima	1	0.03	0	0.00	1	0.03
Nakhon Sawan	0	0.00	1	0.03	1	0.03
Phichit	1	0.03	0	0.00	1	0.03
Phuket	0	0.00	1	0.03	1	0.03
Roi Et	0	0.00	1	0.03	1	0.03
Songkhla	0	0.00	1	0.03	1	0.03
Samut Sakhon	0	0.00	1	0.03	1	0.03
Saraburi	1	0.03	0	0.00	1	0.03
Lao	2	0.07	4	0.14	6	0.21
Total	1,112	38.30	1,790	61.70	2,902	100.00



Note: Other provinces were Kamphaeng Phet, Kanchanaburi, Khon Kaen, Chon Buri, Nakhon Pathom, Nakhon Phanom, Nakhon Ratchasima, Nakhon Sawan, Phichit, Phuket, Roi Et, Songkhla, Samut Sakhon, Saraburi, and Lao


Number and Percentage of Histological verified since 2014 - 2023

Year	Number of new cancer cases	Number of histological verified	Percentage
2014	2,201	1,856	84.33
2015	2,583	2,331	90.24
2016	2,487	2,180	87.66
2017	2,290	2,018	88.12
2018	2,207	1,973	89.40
2019	2,426	2,169	89.41
2020	2,690	2,415	89.78
2021	2,646	2,475	93.54
2022	2,713	2,542	93.73
2023	2,902	2,739	94.38




Type of Diagnosis, 2023

Type of Diagnosis	Male	Female	Total	Percentage
Histological proof	976	1,567	2,543	94.38
◦ Histology of primary	923	1,659	2,582	88.97
◦ Histology of metastasis	66	41	107	3.69
◦ Cytology and hematology	21	29	50	1.72
No histological proof	99	71	170	5.62
◦ Clinical investigation	100	56	156	5.38
◦ Surgery without histology	2	5	7	0.24
Total	1,112	1,790	2,902	100.00




Staging of new cancer patients in Lampang Cancer Hospital, 2023




Extension of new cancer patients in Lampang Cancer Hospital, 2023

Extension	Male	Female	Total	%
Localized	108	483	591	20.37
Direct extension	50	122	172	5.93
Regional lymph node	254	633	887	30.56
Distant metastasis	496	458	954	32.87
Not applicable	20	23	43	1.48
Not known	184	71	255	8.79
Total	1,112	1,790	2,902	100.00



Metastasis sites in stage IV, 2023


Metastasis site	Male	Female	Total	%
Distant lymph node	62	62	124	13.00
Bone	120	128	248	26.00
Liver	25	13	38	3.98
Lung/Pleura	42	43	85	8.91
Brain	45	33	78	8.18
Peritoneum	3	5	8	0.84
Other	9	8	17	1.78
Multiple sites	187	166	353	37.00
Not known site	3	0	3	0.31
Total	496	458	954	100.00




Type of treatment in Lampang Cancer Hospital, 2023

Treatment	Male	Female	Total	%
Surgery	4	50	54	1.86
Radiotherapy	372	926	1298	44.73
Systemic therapy	124	160	284	9.79
◦ Chemotherapy	114	147	261	8.99
◦ Targeted Therapy	16	25	41	1.41
◦ Immunotherapy	1	2	3	0.10
Concurrent RT	284	284	568	19.57
I-131	19	82	101	3.48
Palliative care	214	189	403	13.89
Hormone	6	9	15	0.52
Consult/Investigation	316	489	805	27.74
◦ Investigation	243	431	674	23.23
◦ Consult	73	59	132	4.55

Note: Investigation = CT/Bone Scan/Ultrasound/Mammogram/Total body scan



10 Leading new cancer patients in Lampang Cancer Hospital by Sex, 2023





Male			
Rating	Cancer sites	Number	%
1	C18-20 Colorectal	216	19.4
2	C61 Prostate	209	18.8
3	C33-34 Trachea, Bronchus and lung	201	18.1
4	C09-14 Pharynx	80	7.2
5	C22,C24 Liver and bile duct	71	6.4
6	C00-06 Oral cavity	51	4.6
7	C15 Oesophagus	34	3.1
8	C73 Thyroid	32	2.9
9	C81-86,C88,C96 Lymphoma	28	2.5
10	C43-44 Skin	24	2.2

Female			
Rating	Cancer sites	Number	%
1	C50 Breast	824	46.0
2	C53 Cervix uteri	220	12.2
3	C33-34 Trachea, Bronchus and lung	143	8.0
4	C18-20 Colorectal	127	7.1
5	C73 Thyroid	123	6.9
6	C54 Corpus uteri	108	6.0
7	C09-14 Pharynx	31	1.7
8	C81-86,C88,C96 Lymphoma	29	1.6
9	C00-06 Oral cavity	26	1.5
10	C22,C24 Liver and bile duct	17	0.9

Note: Lpch has Colorectal cancer screening policy and Nakornping has referred Prostate cancer for investigation in LPCH this year.

10 Leading new cancer patients in Lampang Cancer Hospital (Both sex), 2023




Rating	Cancer sites	Number	Percentage
1	C50 Breast	827	28.5
2	C33-34 Trachea, Bronchus and lung	344	11.9
3	C18-20 Colorectal	343	11.8
4	C53 Cervix uteri	220	7.6
5	C61 Prostate	209	7.2
6	C73 Thyroid	155	5.3
7	C09-14 Pharynx	111	3.8
8	C54 Corpus uteri	108	3.7
9	C22,C24 Liver and bile duct	88	3.0
10	C00-06 Oral cavity	77	2.7

Common Cancer Sites in Lampang Cancer Hospital 2023


Head and Neck Cancer ICD-O: C00-14, C30-32

Trend of new head and neck cancer in Lampang Cancer Hospital 10 years (since 2014 - 2023)




Number of new head and neck cancer patients in Lampang Cancer Hospital by age and sex, 2023

Age group (Year)	Male		Female		Both sex	
	N	%	N	%	N	%
10 - 14	0	0.00	1	0.43	1	0.43
15 - 19	1	0.43	0	0.00	1	0.43
20 - 24	0	0.00	1	0.43	1	0.43
25 - 29	3	1.29	1	0.43	4	1.72
30 - 34	0	0.00	1	0.43	1	0.43
35 - 39	7	3.00	4	1.72	11	4.72
40 - 44	7	3.00	4	1.72	11	4.72
45 - 49	19	8.16	7	3.00	26	11.16
50 - 54	21	9.01	10	4.29	31	13.30
55 - 59	22	9.44	11	4.72	33	14.16
60 - 64	34	14.59	11	4.72	45	19.31
65 - 69	24	10.30	8	3.43	32	13.73
70 - 74	9	3.86	3	1.29	12	5.15
75 - 79	11	4.72	5	2.15	16	6.87
80 - 84	4	1.72	2	0.86	6	2.58
85+	0	0.00	2	0.86	2	0.86
Total	162	69.52	71	30.48	233	100.00



Type of diagnosis of new head and neck cancer patients in Lampang Cancer Hospital , 2023


Type of Diagnosis	Male	Female	Total	%
Clinical investigation	1	0	1	0.43
Cytology and hematology	2	1	3	1.29
Histology of metastasis	1	1	2	0.86
Histology of primary	158	69	227	97.42
Total	162	71	233	100.00



Treatment of new head and neck cancer patients in Lampang Cancer Hospital , 2023


Type of treatment	Male	Female	Total	%
Radiotherapy	37	22	59	25.32
Systemic therapy				
◦ Chemotherapy	13	7	20	8.58
Concurrent RT	81	33	114	48.93
Palliative care	39	13	52	22.32
Consult/Investigation				
◦ Investigation	19	9	28	12.02
◦ Consult	14	4	18	7.73

Note: Investigation = CT/Bone Scan/Ultrasound/Mammogram/Total body scan




Staging of new head and neck cancer patients in Lampung Cancer Hospital, 2023

	Staging	Male	Female	Total	%
●	Stage I	9	7	16	6.87
●	Stage II	8	11	19	8.15
●	Stage III	29	18	47	20.17
●	Stage IV	104	32	136	58.37
●	Unknown Stage	12	3	15	6.44
	Total	162	71	233	100.00




Extension of new head and neck cancer patients in Lampung Cancer Hospital, 2023

	Extension	Male	Female	Total	%
●	Localized	20	18	38	16.31
●	Direct extension	17	8	25	10.73
●	Regional lymph node	85	36	121	51.93
●	Distant metastasis	28	6	34	14.59
●	Not known	12	3	15	6.44
	Total	162	71	233	100.00




Metastasis sites of new head and neck cancer patients in Lampung Cancer Hospital, 2023

	Extension	Male	Female	Total	%
●	Distant lymph node	5	1	6	17.65
●	Bone	7	2	9	26.47
●	Liver	2	0	2	5.88
●	Lung/Pleura	6	2	8	23.53
●	Multiple sites	8	1	9	26.47
	Total	27	6	34	100.00




Colorectal Cancer ICD-O: C18-20

Trend of new colorectal cancer in Lampang Cancer Hospital 20 years (since 2004 - 2023)




Number of new colorectal cancer patients in Lampang Cancer Hospital by age and sex, 2023

Age group (Year)	Male		Female		Both sex	
	N	%	N	%	N	%
25-29	0	0.00	2	0.58	2	0.58
30-34	2	0.58	2	0.58	4	1.16
35-39	4	1.17	1	0.29	5	1.46
40-44	2	0.58	5	1.46	7	2.04
45-49	12	3.51	7	2.05	19	5.56
50-54	15	4.39	11	3.22	26	7.61
55-59	34	9.94	15	4.39	49	14.33
60-64	46	13.45	25	7.31	71	20.76
65-69	44	12.87	24	7.02	68	19.89
70-74	29	8.48	20	5.85	49	14.33
75-79	13	3.80	12	3.51	25	7.31
80-84	11	3.22	2	0.58	13	3.80
85+	3	0.88	1	0.29	4	1.17
Total	215	62.87	127	37.13	342	100.00



Type of diagnosis of new colorectal cancer patients in Lampang Cancer Hospital, 2023


Type of Diagnosis	Male	Female	Total	%
Clinical investigation	5	1	6	1.75
Histology of metastasis	3	1	4	1.17
Histology of primary	207	125	332	97.08
Total	215	127	342	100.00



Treatment of new colorectal cancer patients in Lampang Cancer Hospital, 2023


Type of treatment	Male	Female	Total	%
Surgery	3	8	11	3.22
Radiotherapy	38	24	62	18.13
Systemic therapy				
◦ Chemotherapy	15	16	31	9.06
◦ Targeted Therapy	0	1	1	0.29
Concurrent RT	134	73	207	60.53
Palliative care	23	21	44	12.87
Consult/Investigation				
Investigation	11	8	19	5.56
Consult	15	4	19	5.56

Note: Investigation = CT/Bone Scan/Ultrasound/Mammogram/Total body scan




Staging of new colorectal cancer patients in Lampang Cancer Hospital, 2023

Staging	Male	Female	Total	%
Stage I	7	6	13	3.80
Stage II	33	29	62	18.13
Stage III	100	49	149	43.57
Stage IV	64	35	99	28.95
Unknown Stage	11	8	19	5.56
Total	215	127	342	100.00




Extension of new colorectal cancer patients in Lampang Cancer Hospital, 2023

Extension	Male	Female	Total	%
Localized	33	27	60	17.54
Direct extension	13	10	23	6.73
Regional lymph node	97	48	145	42.40
Distant metastasis	61	34	95	27.78
Not known	11	8	19	5.56
Total	215	127	342	100.00




Metastasis sites of new colorectal cancer patients in Lampang Cancer Hospital, 2023

Metastasis site	Male	Female	Total	%
Distant lymph node	14	4	18	18.95
Bone	5	3	8	8.42
Liver	14	6	20	21.05
Lung/Pleura	6	5	11	11.58
Brain	1	2	3	3.16
Peritoneum	0	2	2	2.11
Other	2	4	6	6.32
Multiple sites	18	8	26	27.37
Not known site	1		1	1.05
Total	61	34	95	100.00




Liver and bile ducts Cancer ICD-O: C22, C24

Trend of new liver and bile ducts cancer in in Lampang Cancer Hospital 20 years (since 2004 - 2023)




Number of new liver and bile ducts cancer patients in Lampang Cancer Hospital by age and sex, 2023

Age group (Year)	Male		Female		Both sex	
	N	%	N	%	N	%
35-39	1	1.14	0	0.00	1	1.14
40-44	2	2.27	0	0.00	2	2.27
45-49	2	2.27	1	1.14	3	3.41
50-54	11	12.5	2	2.27	13	14.77
55-59	11	12.5	2	2.27	13	14.77
60-64	18	20.45	3	3.41	21	23.86
65-69	14	15.91	6	6.82	20	22.73
70-74	6	6.82	2	2.27	8	9.09
75-79	5	5.68	1	1.14	6	6.82
80-84	1	1.14	0	0.00	1	1.14
Total	71	80.68	17	19.32	88	100.00




Type of diagnosis of new liver and bile ducts cancer patients in Lampang Cancer Hospital, 2023

Type of Diagnosis	Male	Female	Total	%
Clinical investigation	45	8	53	60.23
Cytology and hematology	2	0	2	2.27
Histology of metastasis	4	2	6	6.82
Histology of primary	20	7	27	30.68
Total	71	17	88	100.00



Treatment of new liver and bile ducts cancer patients in Lampang Cancer Hospital, 2023


Type of treatment	Male	Female	Total	%
Radiotherapy	12	4	16	18.18
Systemic therapy				
◦ Chemotherapy	24	7	31	35.23
◦ Targeted Therapy	4	0	4	4.55
Concurrent RT	2	0	2	2.27
Palliative care	34	9	43	48.86
Consult/Investigation				
◦ Investigation	9	2	11	12.50
◦ Consult	11	3	14	15.91



Note: Investigation = CT/Bone Scan/Ultrasound/Mammogram/Total body scan


Staging of new liver and bile ducts cancer patients in Lampang Cancer Hospital, 2023

	Staging	Male	Female	Total	%
●	Stage II	2	0	2	2.27
●	Stage III	0	2	2	2.27
●	Stage IV	56	13	69	78.41
●	Unknown Stage	13	2	15	17.05
	Total	71	17	88	100.00




Extension of new liver and bile ducts cancer patients in Lampang Cancer Hospital, 2023

	Extension	Male	Female	Total	%
●	Localized	2	1	3	3.41
●	Regional lymph node	0	1	1	1.14
●	Distant metastasis	56	13	69	78.41
●	Not known	13	2	15	17.05
	Total	71	17	88	100.00




Metastasis sites of new liver and bile ducts cancer patients in Lampang Cancer Hospital, 2023

	Metastasis site	Male	Female	Total	%
●	Distant lymph node	7	2	9	13.04
●	Bone	7	2	9	13.04
●	Liver	2	1	3	4.35
●	Lung/Pleura	4	1	5	7.25
●	Brain	1	0	1	1.45
●	Peritoneum	1	0	1	1.45
●	Other	1	0	1	1.45
●	Multiple sites	32	7	39	56.52
●	Not known site	1	0	1	1.45
	Total	56	13	69	100.00




Lung Cancer ICD-O: C33 - 34

Trend of new lung cancer in Lampang Cancer Hospital 20 years (since 2004 - 2023)




Number of new lung cancer patients in Lampang Cancer Hospital by age and sex, 2023

Age group (Year)	Male		Female		Both sex	
	N	%	N	%	N	%
20-24	0	0.00	1	0.29	1	0.29
25-29	0	0.00	0	0.00	0	0.00
30-34	1	0.29	4	1.16	5	1.45
35-39	0	0.00	0	0.00	0	0.00
40-44	5	1.45	2	0.58	7	2.03
45-49	4	1.16	9	2.62	13	3.78
50-54	17	4.94	11	3.20	28	8.14
55-59	21	6.10	19	5.52	40	11.62
60-64	41	11.92	34	9.88	75	21.80
65-69	55	15.99	36	10.47	91	26.46
70-74	31	9.02	19	5.52	50	14.54
75-79	17	4.94	8	2.33	25	7.27
80-84	8	2.33	0	0.00	8	2.33
85+	1	0.29	0	0.00	1	0.29
Total	201	58.43	143	41.57	344	100.00



Type of diagnosis of new lung cancer patients in Lampang Cancer Hospital, 2023


Type of Diagnosis	Male	Female	Total	%
Clinical investigation	29	35	64	18.6
Cytology and hematology	16	12	28	8.14
Histology of metastasis	45	23	68	19.77
Histology of primary	111	73	184	53.49
Total	201	143	344	100.00



Treatment of new lung cancer patients in Lampang Cancer Hospital, 2023


Type of treatment	Male	Female	Total	%
Radiotherapy	116	82	198	57.56
Systemic therapy				
◦ Chemotherapy	37	23	60	17.44
◦ Targeted Therapy	12	14	26	7.56
◦ Immunotherapy	1	1	2	0.58
Concurrent RT	18	6	24	6.98
Palliative care	56	28	84	24.42
Consult/Investigation				
◦ Investigation	22	22	44	12.79
◦ Consult	11	8	19	5.52

Note: Investigation = CT/Bone Scan/Ultrasound/Mammogram/Total body scan




Staging of new lung cancer patients in Lampang Cancer Hospital, 2023

Staging	Male	Female	Total	%
Stage I	1	3	4	1.16
Stage II	3	3	6	1.74
Stage III	36	15	51	14.83
Stage IV	157	115	272	79.07
Unknown Stage	4	7	11	3.20
Total	201	143	344	100.00




Extension of new lung cancer patients in Lampang Cancer Hospital, 2023

Extension	Male	Female	Total	%
Localized	4	5	9	2.62
Direct extension	3	2	5	1.45
Regional lymph node	33	14	47	13.66
Distant metastasis	157	115	272	79.07
Not known	4	7	11	3.20
Total	201	143	344	100.00




Metastasis sites of new lung cancer patients in Lampang Cancer Hospital, 2023

Metastasis site	Male	Female	Total	%
Distant lymph node	13	10	23	8.46
Bone	10	18	28	10.29
Liver	2	0	2	0.74
Lung/Pleura	17	12	29	10.66
Brain	27	20	47	17.28
Other	4	1	5	1.84
Multiple sites	83	54	137	50.37
Not known site	1	0	1	0.37
Total	157	115	272	100.00




Breast Cancer ICD-O: C50

Trend of new breast cancer in Lampang Cancer Hospital 20 years (since 2004 - 2023)




Number of new breast cancer patients in Lampang Cancer Hospital by age and sex, 2023

Age group (Year)	Male		Female		Both sex	
	N	%	N	%	N	%
20-24	0	0.00	2	0.24	2	0.24
25-29	0	0.00	9	1.09	9	1.09
30-34	0	0.00	22	2.66	22	2.66
35-39	0	0.00	44	5.32	44	5.32
40-44	0	0.00	77	9.31	77	9.31
45-49	0	0.00	101	12.21	101	12.21
50-54	0	0.00	122	14.75	122	14.75
55-59	0	0.00	144	17.42	144	17.42
60-64	1	0.12	139	16.81	140	16.93
65-69	2	0.24	89	10.76	91	11.00
70-74	0	0.00	42	5.08	42	5.08
75-79	0	0.00	20	2.42	20	2.42
80-84	0	0.00	8	0.97	8	0.97
85+	0	0.00	5	0.60	5	0.60
Total	3	0.36	824	99.64	827	100.00



Type of diagnosis of new breast cancer patients in Lampang Cancer Hospital, 2023


Type of Diagnosis	Male	Female	Total	%
Clinical investigation	0	1	1	0.12
Surgery without histology	0	3	3	0.36
Cytology and hematology	0	4	4	0.49
Histology of metastasis	0	3	3	0.36
Histology of primary	3	813	816	98.67
Total	3	824	827	100.00



Treatment of new breast cancer patients in Lampang Cancer Hospital, 2023


Type of treatment	Male	Female	Total	%
Surgery	0	41	41	4.96
Radiotherapy	2	430	432	52.24
Systemic therapy				
◦ Chemotherapy	0	59	59	7.13
◦ Targeted Therapy	0	10	10	1.21
◦ Immunotherapy	0	1	1	0.12
Palliative care	0	63	63	7.62
Hormone	0	9	9	1.09
Consult/Investigation				
◦ Investigation	1	344	345	41.72
◦ Consult	0	17	17	2.06

Note: Investigation = CT/Bone Scan/Ultrasound/Mammogram/Total body scan




Staging of new breast cancer patients in Lampang Cancer Hospital, 2023

	Staging	Male	Female	Total	%
●	Stage IA	0	84	84	10.16
●	Stage IIA	2	178	180	21.76
●	Stage IIB	0	186	186	22.49
●	Stage IIIA	0	110	110	13.30
●	Stage IIIB	0	42	42	5.08
●	Stage IIIC	0	55	55	6.65
●	Stage IVB	1	152	153	18.50
●	Unknown Stage	0	17	17	2.06
	Total	3	824	827	100.00




Comparison number of new breast cancer patients in Lampang Cancer Hospital by staging since 2014 - 2023




Extension of new breast cancer patients in Lampang Cancer Hospital, 2023

Extension	Male	Female	Total	%
Localized	2	220	222	26.85
Direct extension	0	26	26	3.14
Regional lymph node	0	400	400	48.37
Distant metastasis	1	162	163	19.71
Not known	0	16	16	1.93
Total	3	824	827	100.00




Metastasis sites of new breast cancer patients in Lampang Cancer Hospital, 2023

Metastasis site	Male	Female	Total	%
Distant lymph node	0	14	14	8.59
Bone	0	94	94	57.67
Liver	0	4	4	2.45
Lung/Pleura	0	11	11	6.75
Brain	0	5	5	3.07
Other	0	1	1	0.61
Multiple sites	1	33	34	20.86
Total	1	162	163	100.00




Cervical Cancer ICD-O: C53

Trend of new cervical cancer in Lampang Cancer Hospital 20 years (since 2004 - 2023)




Number of new cervical cancer patients in Lampang Cancer Hospital, 2023

Age group (Year)	Both sex	
	N	%
20-24	1	0.45
25-29	3	1.36
30-34	7	3.18
35-39	15	6.82
40-44	26	11.82
45-49	24	10.91
50-54	30	13.64
55-59	48	21.82
60-64	26	11.82
65-69	15	6.82
70-74	9	4.09
75-79	9	4.09
80-84	6	2.73
85+	1	0.45
Total	220	100.00



Type of diagnosis of new cervical cancer patients in Lampang Cancer Hospital, 2023


Type of Diagnosis	Total	%
Surgery without histology	1	0.45
Cytology and hematology	2	0.91
Histology of metastasis	1	0.45
Histology of primary	216	98.19
Total	220	100.00



Treatment of new cervical cancer patients in Lampang Cancer Hospital, 2023


Type of treatment	Total	%
Radiotherapy	166	75.45
Systemic therapy		
◦ Chemotherapy	11	5.00
Concurrent RT	150	68.18
Palliative care	19	8.64
Consult/Investigation		
◦ Investigation	3	1.36
◦ Consult	6	4.09

Note: Investigation = CT/Bone Scan/Ultrasound/Mammogram/Total body scan




Staging of new cervical cancer patients in Lampang Cancer Hospital, 2023

Staging	Total	%
Stage IA	2	0.91
Stage IB	24	10.91
Stage IIA	15	6.82
Stage IIB	51	23.18
Stage IIC	1	0.45
Stage IIIA	8	3.64
Stage IIIB	23	10.45
Stage IIIC	50	22.73
Stage IVA	14	6.36
Stage IVB	30	13.64
Unknown Stage	2	0.91
Total	220	100.00




Comparison number of new cervical cancer patients in Lampang Cancer Hospital by staging since 2014 - 2023




Extension of new cervical cancer patients in Lampang Cancer Hospital, 2023

Extension	Total	%
Localized	85	38.64
Direct extension	48	21.82
Regional lymph node	53	24.09
Distant metastasis	32	14.55
Not known	2	0.90
Total	220	100.00




Metastasis sites of new cervical cancer patients in Lampang Cancer Hospital, 2023

Metastasis site	Total	%
Distant lymph node	10	31.25
Bone	2	6.25
Liver	1	3.13
Lung/Pleura	2	6.25
Other	2	6.25
Multiple sites	15	46.87
Total	32	100.00




Thyroid Cancer ICD-O: C73

Trend of new thyroid cancer in Lampang Cancer Hospital 10 years (since 2014 - 2023)




Number of new thyroid cancer patients in Lampang Cancer Hospital by age and sex, 2023

Age group (Year)	Male		Female		Both sex	
	N	%	N	%	N	%
15-19	2	1.29	6	3.87	8	5.16
20-24	2	1.29	9	5.80	11	7.09
25-29	3	1.93	7	4.52	10	6.45
30-34	0	0.00	6	3.87	6	3.87
35-39	2	1.29	11	7.10	13	8.39
40-44	2	1.29	15	9.68	17	10.97
45-49	1	0.65	12	7.74	13	8.39
50-54	3	1.93	9	5.80	12	7.73
55-59	1	0.65	22	14.19	23	14.84
60-64	3	1.93	9	5.80	12	7.73
65-69	5	3.23	4	2.59	9	5.82
70-74	4	2.59	5	3.23	9	5.82
75-79	3	1.93	6	3.87	9	5.80
80-84	0	0.00	2	1.29	2	1.29
85+	1	0.65	0	0.00	1	0.65
Total	32	20.65	123	79.35	155	100.00



Type of diagnosis of new thyroid cancer patients in Lampang Cancer Hospital, 2023


Type of Diagnosis	Male	Female	Total	%
Clinical investigation	0	1	1	0.65
Surgery without histology	1	0	1	0.65
Cytology and hematology	1	2	3	1.93
Histology of metastasis	0	2	2	1.29
Histology of primary	30	118	148	95.48
Total	32	123	155	100.01



Treatment of new thyroid cancer patients in Lampang Cancer Hospital, 2023


Type of treatment	Male	Female	Total	%
Radiotherapy	3	4	7	4.52
I-131	19	82	101	65.16
Palliative care	1	3	4	2.58
Consult/Investigation				
◦ Investigation	10	31	41	26.45
◦ Consult	0	5	5	3.23

Note: Investigation = CT/Bone Scan/Ultrasound/Mammogram/Total body scan




Staging of new thyroid cancer patients in Lampang Cancer Hospital, 2023

	Staging	Male	Female	Total	%
●	Stage I	10	74	84	54.19
●	Stage II	14	24	38	24.51
●	Stage III	2	1	3	1.94
●	Stage IV	6	23	29	18.71
●	Unknown Stage	0	1	1	0.65
	Total	32	123	155	100.00




Extension of new thyroid cancer patients in Lampang Cancer Hospital, 2023

	Extension	Male	Female	Total	%
●	Localized	10	48	58	37.41
●	Direct extension	1	3	4	2.58
●	Regional lymph node	12	38	50	32.26
●	Distant metastasis	9	33	42	27.10
●	Not known	0	1	1	0.65
	Total	32	123	155	100.00



Metastasis sites of new thyroid cancer patients in Lampang Cancer Hospital, 2023

	Metastasis site	Male	Female	Total	%
●	Distant lymph node	2	8	10	23.81
●	Bone	1	0	1	2.38
●	Lung/Pleura	0	7	7	16.67
●	Multiple sites	6	18	24	57.14
	Total	9	33	42	100.00



Number of new cancer by age and sex in Lampang Cancer Hospital (Male), 2023

Site	ALL AGE	0- -4	5- -9	10- -14	15- -19	20- -24	25- -29	30- -34	35- -39	40- -44	45- -49	50- -54	55- -59	60- -64	65- -69	70- -74	75- -79	80- -84	85+	% of Total	ICD (10th)
Lip	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0.2	C00
Tongue	34	0	0	0	0	0	0	0	2	1	4	3	5	6	6	1	4	2	0	3.1	C01-02
Mouth	15	0	0	0	0	0	0	0	0	1	0	3	2	2	4	2	1	0	0	1.3	C03-06
Salivary glands	2	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0.2	C07-08
Tonsil	11	0	0	0	0	0	0	0	0	0	4	4	1	1	1	0	0	0	0	1.0	C09
Other oropharynx	6	0	0	0	0	0	0	0	1	0	0	1	2	1	1	0	0	0	0	0.5	C10
Nasopharynx	48	0	0	0	1	0	3	0	3	3	7	5	6	7	8	2	1	2	0	4.3	C11
Hypopharynx	14	0	0	0	0	0	0	0	0	2	2	0	3	4	2	1	0	0	0	1.3	C12-13
Pharynx unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C14
Oesophagus	34	0	0	0	0	0	0	1	0	0	0	7	7	6	8	3	2	0	0	3.1	C15
Stomach	16	0	0	0	0	0	0	0	0	1	1	1	3	4	3	2	1	0	0	1.4	C16
Small intestine	2	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0.2	C17
Colon	40	0	0	0	0	0	0	0	2	0	4	2	7	5	8	8	1	3	0	3.6	C18
Rectum	176	0	0	0	0	0	0	2	2	2	8	13	27	41	36	21	12	8	3	15.8	C19-20
Anus	9	0	0	0	0	0	0	0	1	0	2	1	1	2	3	0	0	0	0	0.8	C21
Liver and bile duct	71	0	0	0	0	0	0	0	1	2	2	11	11	18	14	6	5	1	0	6.4	C22,C24
Gallbladder	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.1	C23
Pancreas	5	0	0	0	0	0	0	0	0	0	0	0	0	0	1	4	0	0	0	0.4	C25
Nose, sinuses etc.	7	0	0	0	0	0	0	0	1	0	1	0	0	2	1	0	2	0	0	0.6	C30-31
Larynx	21	0	0	0	0	0	0	0	0	0	1	3	3	9	0	2	3	0	0	1.9	C32
Trachea, Bronchus and lung	201	0	0	0	0	0	0	1	0	5	4	17	21	41	55	31	17	8	1	18.1	C33-34
Other thoracic organs	2	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0.2	C37-38
Bone	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	C40-C41
Melanoma of skin	6	0	0	0	0	0	0	0	0	1	0	3	0	0	0	1	0	0	1	0.5	C43
Other skin	18	0	0	0	0	0	0	0	0	1	1	2	1	2	3	3	2	1	2	1.6	C44
Connective tissue	15	0	0	0	1	1	1	0	0	1	0	2	1	2	3	0	1	2	0	1.3	C47,C49
Breast	3	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	0	0.3	C50
Vulva	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C51
Vagina	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C52
Cervix uteri	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C53
Corpus uteri	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C54
Ovary	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C56
Other female genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C57
Penis	5	0	0	0	0	0	0	1	0	1	0	0	1	1	0	1	0	0	0	0.4	C60
Prostate	209	0	0	0	0	0	0	0	0	0	0	3	14	35	56	51	30	13	7	18.8	C61
Testis	5	0	0	0	1	1	1	0	1	1	0	0	0	0	0	0	0	0	0	0.4	C62
Other male genital organs	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0.2	C63
Kidney	8	0	0	0	0	0	0	0	0	0	1	0	0	2	3	2	0	0	0	0.7	C64
Renal pelvis	2	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0.2	C65
Ureter	3	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	0	0.3	C66
Bladder	19	0	0	0	0	0	0	0	0	0	0	0	1	6	3	2	2	2	3	1.7	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C68
Brain, nervous system	20	0	0	1	2	0	2	0	0	0	1	3	3	3	3	2	0	0	0	1.8	C70-72
Thyroid	32	0	0	0	2	2	3	0	2	2	1	3	1	3	5	4	3	0	1	2.9	C73
Adrenal gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C74
Hodgkin disease	2	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0.2	C81
Non-Hodgkin lymphoma	22	0	0	0	0	1	0	1	2	1	2	1	3	5	4	0	2	0	0	2.0	C82-85,C96
T/NK-cell lymphoma	3	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0	0	0	0.3	C86
MALT	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.1	C88
Multiple myeloma	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0.1	C90
Lymphoid leukemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C91
Other and unspecified	17	0	0	0	0	0	0	0	0	0	1	0	2	3	5	3	3	0	0	1.5	O&U
All sites	1,112	0	0	1	7	7	11	6	18	25	47	91	132	220	242	153	92	42	18	100.0	ALL

Number of new cancer by age and sex in Lampang Cancer Hospital (Female), 2023

Site	ALL AGE	0- -4	5- -9	10- -14	15- -19	20- -24	25- -29	30- -34	35- -39	40- -44	45- -49	50- -54	55- -59	60- -64	65- -69	70- -74	75- -79	80- -84	85+	% of Total	ICD (10th)
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C00
Tongue	14	0	0	0	0	0	0	0	0	0	4	2	2	1	2	0	3	0	0	0.8	C01-02
Mouth	12	0	0	0	0	0	0	0	0	1	0	3	3	0	3	0	0	1	1	0.7	C03-06
Salivary glands	8	0	0	1	0	1	0	0	0	1	1	2	1	0	0	0	1	0	0	0.4	C07-08
Tonsil	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C09
Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C10
Nasopharynx	26	0	0	0	0	0	1	1	4	2	2	2	2	6	3	1	1	1	0	1.5	C11
Hypopharynx	4	0	0	0	0	0	0	0	0	0	0	1	2	1	0	0	0	0	0	0.2	C12-13
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C14
Oesophagus	7	0	0	0	0	0	0	0	0	0	1	2	2	0	2	0	0	0	0	0.4	C15
Stomach	11	0	0	0	0	0	0	1	0	0	0	4	2	1	0	1	2	0	0	0.6	C16
Small intestine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C17
Colon	25	0	0	0	0	0	0	0	0	0	3	1	6	7	4	2	1	1	0	1.4	C18
Rectum	102	0	0	0	0	0	2	2	1	5	4	10	9	18	20	18	11	1	1	5.7	C19-20
Anus	12	0	0	0	0	0	0	0	1	1	2	1	3	0	3	0	0	1	0	0.7	C21
Liver and bile duct	17	0	0	0	0	0	0	0	0	0	1	2	2	3	6	2	1	0	0	0.9	C22,C24
Gallbladder	2	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0.1	C23
Pancreas	7	0	0	0	0	0	0	0	0	0	0	1	2	2	0	0	1	1	0	0.4	C25
Nose, sinuses etc.	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0.2	C30-31
Larynx	3	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0	0	0.2	C32
Trachea, Bronchus and lung	143	0	0	0	0	1	0	4	0	2	9	11	19	34	36	19	8	0	0	7.9	C33-34
Other thoracic organs	6	0	0	0	0	0	0	0	0	0	1	0	2	0	1	2	0	0	0	0.3	C37-38
Bone	3	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	0	0.2	C40-C41
Melanoma of skin	5	0	0	0	0	0	0	0	0	0	0	0	1	1	2	1	0	0	0	0.3	C43
Other skin	10	0	0	0	0	0	0	0	0	0	0	0	0	1	1	4	3	0	1	0.6	C44
Connective tissue	7	0	0	0	0	0	0	1	1	0	0	0	2	3	0	0	0	0	0	0.4	C47,C49
Breast	824	0	0	0	0	2	9	22	44	77	101	122	144	139	89	42	20	8	5	46.0	C50
Vulva	7	0	0	0	0	0	0	0	0	0	0	0	3	1	1	1	0	1	0	0.4	C51
Vagina	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0.1	C52
Cervix uteri	220	0	0	0	0	1	3	7	15	26	24	30	48	26	15	9	9	6	1	12.2	C53
Corpus uteri	108	0	0	0	0	0	0	4	2	2	7	12	20	22	19	13	6	1	0	6.0	C54
Ovary	11	0	0	0	0	0	0	0	1	0	0	5	4	1	0	0	0	0	0	0.6	C56
Other female genital organs	2	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0.1	C57
Penis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C60
Prostate	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C61
Testis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C62
Other male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C63
Kidney	5	1	0	0	0	0	0	0	0	0	0	0	2	1	1	0	0	0	0	0.3	C64
Renal pelvis	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.1	C65
Ureter	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.1	C66
Bladder	5	0	0	0	0	0	0	0	0	0	0	0	0	0	3	0	0	2	0	0.3	C67
Other urinary organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.1	C68
Brain, nervous system	8	0	0	0	0	0	0	0	0	0	0	3	2	0	1	2	0	0	0	0.4	C70-72
Thyroid	123	0	0	0	6	9	7	6	11	15	12	9	22	9	4	5	6	2	0	6.8	C73
Adrenal gland	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.1	C74
Hodgkin disease	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C81
Non-Hodgkin lymphoma	27	0	0	0	0	1	0	3	0	1	0	4	5	3	3	5	2	0	0	1.5	C82-85,C96
T/NK-cell lymphoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C86
MALT	2	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0.1	C88
Multiple myeloma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0.1	C90
Lymphoid leukemia	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0.1	C91
Other and unspecified	10	0	0	0	0	0	0	0	0	0	0	1	2	1	1	4	0	0	1	0.6	O&U
All sites	1,790	1	0	1	6	15	22	51	80	134	172	230	316	286	228	134	76	27	11	100.0	ALL

Pathology according to site and sex, 2023

Pathology and Sites	Male	Female	Total
Total	1,112	1,790	2,902
C00 LIP	2	0	2
8000: No histological proof	1	0	1
8070: Squamous cell carcinoma, NOS	1	0	1
C01 BASE OF TONGUE	3	0	3
8070: Squamous cell carcinoma, NOS	3	0	3
C02 OTHER AND UNSPECIFIED PARTS OF TONGUE	31	14	45
8070: Squamous cell carcinoma, NOS	30	14	44
8074: Squamous cell carcinoma, spindle cell	1	0	1
C03 GUM	3	2	5
8070: Squamous cell carcinoma, NOS	3	2	5
C04 FLOOR OF MOUTH	5	2	7
8070: Squamous cell carcinoma, NOS	5	2	7
C05 PALATE	3	3	6
8070: Squamous cell carcinoma, NOS	3	1	4
8430: Mucoepidermoid carcinoma	0	1	1
8982: Malignant myoepithelioma	0	1	1
C06 OTHER AND UNSPECIFIED PARTS OF MOUTH	4	5	9
8070: Squamous cell carcinoma, NOS	4	4	8
8200: Adenoid cystic carcinoma	0	1	1
C07 PAROTID GLAND	2	7	9
8082: Lymphoepithelial carcinoma	0	2	2
8140: Adenocarcinoma, NOS	0	2	2
8200: Adenoid cystic carcinoma	1	0	1
8430: Mucoepidermoid carcinoma	0	1	1
8500: Salivary duct carcinoma	1	0	1
8550: Acinic cell adenocarcinoma	0	1	1
8562: Epithelial-myoepithelial carcinoma	0	1	1
C08 OTHER AND UNSPECIFIED MAJOR SALIVARY GLANDS	0	1	1
8010: Carcinoma, NOS	0	1	1
C09 TONSIL	11	1	12
8070: Squamous cell carcinoma, NOS	9	1	10
8071: Squamous cell carcinoma, keratinizing, NOS	1	0	1
8072: Squamous cell carcinoma, large cell, nonkeratinizing, NOS	1	0	1
C10 OROPHARYNX	6	0	6
8070: Squamous cell carcinoma, NOS	4	0	4
8071: Squamous cell carcinoma, keratinizing, NOS	1	0	1
8802: Pleomorphic cell sarcoma	1	0	1
C11 NASOPHARYNX	48	26	74
8010: Carcinoma, NOS	1	0	1
8020: Carcinoma, undifferentiated type, NOS	6	1	7
8070: Squamous cell carcinoma, NOS	2	1	3
8072: Squamous cell carcinoma, large cell, nonkeratinizing, NOS	39	23	62
8802: Pleomorphic cell sarcoma	0	1	1
C12 PYRIFORM SINUS	5	0	5
8070: Squamous cell carcinoma, NOS	4	0	4
8071: Squamous cell carcinoma, keratinizing, NOS	1	0	1
C13 HYPOPHARYNX	9	4	13
8070: Squamous cell carcinoma, NOS	8	4	12
8074: Squamous cell carcinoma, spindle cell	1	0	1

Pathology and Sites	Male	Female	Total
C14 OTHER AND ILL-DEFINED SITES IN LIP, ORAL CAVITY AND PHARYNX	1	0	1
8070: Squamous cell carcinoma, NOS	1	0	1
C15 ESOPHAGUS	34	7	41
8000: No histological proof	1	0	1
8010: Carcinoma, NOS	1	0	1
8070: Squamous cell carcinoma, NOS	24	7	31
8072: Squamous cell carcinoma, large cell, nonkeratinizing, NOS	1	0	1
8140: Adenocarcinoma, NOS	5	0	5
8560: Adenosquamous carcinoma	2	0	2
C16 STOMACH	16	11	27
8000: No histological proof	0	1	1
8140: Adenocarcinoma, NOS	12	7	19
8145: Carcinoma, diffuse type	1	0	1
8211: Tubular adenocarcinoma	1	0	1
8490: Signet ring cell carcinoma	2	3	5
C17 SMALL INTESTINE	2	0	2
8936: Gastrointestinal stromal sarcoma	2	0	2
C18 COLON	40	25	65
8000: No histological proof	4	0	4
8010: Carcinoma, NOS	1	0	1
8140: Adenocarcinoma, NOS	34	24	58
8481: Mucin-producing adenocarcinoma	1	1	2
C19 RECTOSIGMOID JUNCTION	7	5	12
8140: Adenocarcinoma, NOS	7	5	12
C20 RECTUM	168	97	265
8000: No histological proof	1	1	2
8010: Carcinoma, NOS	1	0	1
8140: Adenocarcinoma, NOS	160	91	251
8480: Mucinous adenocarcinoma	1	1	2
8481: Mucin-producing adenocarcinoma	2	2	4
8490: Signet ring cell carcinoma	3	1	4
8936: Gastrointestinal stromal sarcoma	0	1	1
C21 ANUS AND ANAL CANAL	10	12	22
8000: No histological proof	1	0	1
8070: Squamous cell carcinoma, NOS	4	6	10
8071: Squamous cell carcinoma, keratinizing, NOS	0	1	1
8140: Adenocarcinoma, NOS	4	4	8
8481: Mucin-producing adenocarcinoma	1	0	1
8240: Neuroendocrine tumor, NOS	0	1	1
C22 LIVER AND INTRAHEPATIC BILE DUCTS	68	16	84
8000: No histological proof	45	8	53
8140: Adenocarcinoma, NOS	7	2	9
8160: Cholangiocarcinoma	10	5	15
8170: Hepatocellular carcinoma, NOS	6	1	7
C23 GALLBLADDER	1	2	3
8000: No histological proof	0	1	1
8140: Adenocarcinoma, NOS	1	1	2

Pathology and Sites	Male	Female	Total
C24 OTHER AND UNSPECIFIED PARTS OF BILIARY TRACT	3	1	4
8140: Adenocarcinoma, NOS	1	1	2
8160: Cholangiocarcinoma	1	0	1
8560: Adenosquamous carcinoma	1	0	1
C25 PANCREAS	5	7	12
8000: No histological proof	3	3	6
8140: Adenocarcinoma, NOS	1	4	5
8480: Mucinous adenocarcinoma	1	0	1
C30 NASAL CAVITY AND MIDDLE EAR	6	1	7
8020: Carcinoma, undifferentiated type, NOS	1	0	1
8041: Small cell neuroendocrine carcinoma	1	0	1
8070: Squamous cell carcinoma, NOS	2	1	3
9133: Epithelioid hemangioendothelioma, malignant	1	0	1
9719: NK/T-cell lymphoma, nasal and nasal-type	1	0	1
C31 ACCESSORY SINUSES	2	2	4
8041: Small cell neuroendocrine carcinoma	1	0	1
8070: Squamous cell carcinoma, NOS	0	2	2
8200: Adenoid cystic carcinoma	1	0	1
C32 LARYNX	21	3	24
8070: Squamous cell carcinoma, NOS	21	3	24
C34 BRONCHUS AND LUNG	201	143	344
8000: No histological proof	29	35	64
8010: Carcinoma, NOS	6	3	9
8013: Large cell neuroendocrine carcinoma	1	0	1
8041: Small cell carcinoma, NOS	24	5	29
8046: Non-small cell carcinoma	30	19	49
8070: Squamous cell carcinoma, NOS	29	6	35
8072: Squamous cell carcinoma, large cell, nonkeratinizing, NOS	1	1	2
8083: Basaloid squamous cell carcinoma	1	0	1
8140: Adenocarcinoma, NOS	74	66	140
8200: Adenoid cystic carcinoma	0	1	1
8230: Solid carcinoma, NOS	1	1	2
8250: Lepidic adenocarcinoma	0	1	1
8253: Bronchiolo-alveolar carcinoma, mucinous	0	1	1
8260: Papillary adenocarcinoma, NOS	1	0	1
8550: Acinar cell carcinoma	2	2	4
8551: Acinar cell cystadenocarcinoma	2	2	4
C37 THYMUS	1	6	7
8070: Squamous cell carcinoma, NOS	0	1	1
8580: Thymoma, malignant	0	3	3
8582: Thymoma, type AB, malignant	1	1	2
8585: Thymoma, type B3, malignant	0	1	1
C38 HEART, MEDIASTINUM, AND PLEURA	1	1	2
8246: Neuroendocrine carcinoma	1	0	1
9679: Mediastinal large B-cell lymphoma	0	1	1
C41 BONES, JOINTS AND ARTICULAR CARTILAGE OF OTHER AND UNSPECIFIED SITES	1	3	4
9220: Chondrosarcoma, NOS	1	0	1
9260: Ewing sarcoma	0	1	1
9370: Chordoma, NOS	0	2	2

Pathology and Sites	Male	Female	Total
C42 HEMATOPOIETIC AND RETICULOENDOTHELIAL SYSTEMS	1	3	4
9732: Multiple myeloma	1	2	3
9823: Chronic lymphocytic leukemia	0	1	1
C44 SKIN	24	15	39
8051: Verrucous carcinoma, NOS	0	1	1
8070: Squamous cell carcinoma, NOS	8	5	13
8083: Basaloid squamous cell carcinoma	0	1	1
8090: Basal cell carcinoma, NOS	4	1	5
8092: Infiltrating basal cell carcinoma, NOS	0	1	1
8094: Basosquamous carcinoma	1	0	1
8097: Basal cell carcinoma, nodular	0	1	1
8402: Hidradenocarcinoma	1	0	1
8720: Malignant melanoma, NOS	5	5	10
8744: Acral lentiginous melanoma, malignant	1	0	1
8832: Dermatofibrosarcoma, NOS	4	0	4
C47 PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM	2	1	3
9540: Malignant peripheral nerve sheath tumor	1	1	2
9560: Malignant schwannoma, NOS	1	0	1
C48 RETROPERITONEUM AND PERITONEUM	0	1	1
8461: Primary serous papillary carcinoma of peritoneum	0	1	1
C49 CONNECTIVE, SUBCUTANEOUS AND OTHER SOFT TISSUES	14	6	20
8801: Spindle cell sarcoma	0	1	1
8802: Pleomorphic cell sarcoma, NOS	3	1	4
8810: Fibrosarcoma, NOS	2	0	2
8850: Liposarcoma, NOS	1	0	1
8851: Liposarcoma, well differentiated	1	0	1
8852: Myxoid liposarcoma	0	1	1
8854: Pleomorphic liposarcoma	1	0	1
8858: Dedifferentiated liposarcoma	2	0	2
8890: Leiomyosarcoma, NOS	1	3	4
9040: Synovial sarcoma, NOS	2	0	2
9120: Hemangiosarcoma	1	0	1
C50 BREAST	3	824	827
8000: No histological proof	0	4	4
8010: Carcinoma, NOS	0	4	4
8032: Spindle cell carcinoma, NOS	0	1	1
8070: Squamous cell carcinoma, NOS	0	1	1
8140: Adenocarcinoma, NOS	0	3	3
8201: Cribriform carcinoma	0	2	2
8211: Tubular adenocarcinoma	0	1	1
8480: Mucinous adenocarcinoma	1	2	3
8490: Signet ring cell carcinoma	0	1	1
8500: Invasive ductal carcinoma, NOS	2	769	771
8503: Intraductal papillary adenocarcinoma with invasion	0	7	7
8504: Intracystic carcinoma, NOS	0	4	4
8507: Invasive micropapillary carcinoma	0	3	3
8520: Lobular carcinoma, NOS	0	15	15
8522: Infiltrating duct and lobular carcinoma	0	2	2
8575: Metaplastic carcinoma, NOS	0	2	2
9020: Phyllodes tumor, malignant	0	3	3

Pathology and Sites	Male	Female	Total
C51 VULVA	0	7	7
8070: Squamous cell carcinoma, NOS	0	3	3
8071: Squamous cell carcinoma, keratinizing, NOS	0	1	1
8720: Malignant melanoma, NOS	0	3	3
C52 VAGINA	0	2	2
8070: Squamous cell carcinoma, NOS	0	1	1
8140: Adenocarcinoma, NOS	0	1	1
C53 CERVIX UTERI	0	220	220
8000: No histological proof	0	1	1
8010: Carcinoma, NOS	0	2	2
8041: Small cell neuroendocrine carcinoma	0	2	2
8070: Squamous cell carcinoma, NOS	0	172	172
8071: Squamous cell carcinoma, keratinizing, NOS	0	1	1
8072: Squamous cell carcinoma, large cell, nonkeratinizing, NOS	0	5	5
8083: Basaloid squamous cell carcinoma	0	1	1
8140: Adenocarcinoma, NOS	0	28	28
8380: Endometrioid carcinoma	0	1	1
8384: Adenocarcinoma, endocervical type	0	2	2
8560: Adenosquamous carcinoma	0	4	4
8574: Adenocarcinoma admixed with neuroendocrine carcinoma	0	1	1
C54 CORPUS UTERI	0	108	108
8020: Carcinoma, undifferentiated type, NOS	0	1	1
8140: Adenocarcinoma, NOS	0	3	3
8310: Clear cell adenocarcinoma, NOS	0	1	1
8380: Endometrioid carcinoma	0	89	89
8441: Serous cystadenocarcinoma, NOS	0	9	9
8980: Carcinosarcoma, NOS	0	5	5
C56 OVARY	0	11	11
8000: No histological proof	0	1	1
8140: Adenocarcinoma, NOS	0	3	3
8310: Clear cell adenocarcinoma, NOS	0	1	1
8380: Endometrioid carcinoma	0	2	2
8441: Serous cystadenocarcinoma, NOS	0	2	2
8461: High grade serous carcinoma	0	1	1
8480: Mucinous adenocarcinoma	0	1	1
C57 OTHER AND UNSPECIFIED FEMALE GENITAL ORGANS	0	2	2
8441: Serous cystadenocarcinoma, NOS	0	1	1
8980: Carcinosarcoma, NOS	0	1	1
C60 PENIS	5	0	5
8051: Verrucous carcinoma, NOS	1	0	1
8070: Squamous cell carcinoma, NOS	4	0	4
C61 PROSTATE GLAND	209	0	209
8000: No histological proof	3	0	3
8010: Carcinoma, NOS	3	0	3
8140: Adenocarcinoma, NOS	160	0	160
8490: Mucinous carcinoma, signet ring cell type	1	0	1
8550: Acinar cell carcinoma	42	0	42

Pathology and Sites	Male	Female	Total
C62 TESTIS	5	0	5
9061: Seminoma, NOS	1	0	1
9064: Germinoma	2	0	2
9085: Mixed germ cell tumor	2	0	2
C63 OTHER AND UNSPECIFIED MALE GENITAL ORGANS	2	0	2
8140: Adenocarcinoma, NOS	1	0	1
8481: Mucin-producing adenocarcinoma	1	0	1
C64 KIDNEY	8	5	13
8000: No histological proof	2	0	2
8010: Carcinoma, NOS	1	0	1
8120: Transitional cell carcinoma, NOS	2	3	5
8312: Renal cell carcinoma	3	1	4
8960: Wilms tumor	0	1	1
C65 RENAL PELVIS	2	1	3
8070: Squamous cell carcinoma, NOS	2	0	2
8120: Transitional cell carcinoma, NOS	0	1	1
C66 Ureter	3	1	4
8120: Urothelial carcinoma, NOS	1	1	2
8130: Papillary transitional cell carcinoma	2	0	2
C67 BLADDER	19	5	24
8010: Carcinoma, NOS	1	0	1
8070: Squamous cell carcinoma, NOS	1	0	1
8120: Transitional cell carcinoma, NOS	5	3	8
8130: Papillary urothelial carcinoma	11	2	13
8480: Mucinous adenocarcinoma	1	0	1
C68 OTHER AND UNSPECIFIED URINARY ORGANS	0	1	1
8120: Urothelial carcinoma, NOS	0	1	1
C69 EYE AND ADNEXA	0	1	1
9680: Malignant lymphoma, large B-cell, diffuse, NOS	0	1	1
C70 MENINGES	1	1	2
9530: Meningioma, malignant	1	0	1
9538: Papillary meningioma	0	1	1
C71 BRAIN	20	10	30
9380: Glioma, malignant	3	1	4
9400: Astrocytoma, NOS	1	0	1
9411: Gemistocytic astrocytoma	0	1	1
9440: Glioblastoma, NOS	10	4	14
9442: Gliosarcoma	1	0	1
9450: Oligodendroglioma	1	1	2
9470: Medulloblastoma, NOS	2	0	2
9680: Malignant lymphoma, large B-cell, diffuse, NOS	2	2	4
9699: Marginal zone B-cell lymphoma, NOS	0	1	1
C72 SPINAL CORD, CRANIAL NERVES, AND OTHER PARTS OF CENTRAL NERVOUS SYSTEM	1	0	1
9680: Malignant lymphoma, large B-cell, diffuse, NOS	1	0	1

Pathology and Sites	Male	Female	Total
C73 THYROID GLAND	32	123	155
8000: No histological proof	1	1	2
8010: Carcinoma, NOS	0	2	2
8020: Anaplastic undifferentiated carcinoma	1	0	1
8260: Papillary adenocarcinoma, NOS	13	65	78
8290: Oxyphilic adenocarcinoma	1	1	2
8330: Follicular adenocarcinoma, NOS	3	4	7
8331: Follicular adenocarcinoma, well differentiated	0	1	1
8335: Follicular carcinoma, minimally invasive	1	3	4
8337: Poorly differentiated thyroid carcinoma	1	1	2
8340: Papillary carcinoma, follicular variant	9	37	46
8341: Papillary microcarcinoma	1	5	6
8343: Papillary carcinoma, encapsulated	0	1	1
8344: Papillary carcinoma, tall cell	1	2	3
C74 ADRENAL GLAND	0	1	1
8370: Adrenal cortical carcinoma	0	1	1
C77 LYMPH NODES	24	25	49
9652: Hodgkin lymphoma, mixed cellularity, NOS	1	0	1
9663: Hodgkin lymphoma, nodular sclerosis	1	0	1
9680: Malignant lymphoma, large B-cell, diffuse, NOS	16	18	34
9690: Follicular lymphoma, NOS	1	0	1
9691: Follicular lymphoma, grade 2	1	1	2
9698: Follicular lymphoma, grade 3	0	1	1
9699: Marginal zone B-cell lymphoma, NOS	1	1	2
9702: Mature T-cell lymphoma, NOS	0	3	3
9705: Angioimmunoblastic T-cell lymphoma	2	0	2
9735: Plasmablastic lymphoma	1	0	1
9823: B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma	0	1	1
C80 UNKNOWN PRIMARY SITE	17	9	26
8000: No histological proof	11	5	16
8010: Carcinoma, NOS	1	1	2
8070: Squamous cell carcinoma, NOS	1	0	1
8072: Squamous cell carcinoma, large cell, nonkeratinizing, NOS	1	0	1
8140: Adenocarcinoma, NOS	3	3	6

Publications of cancer registry, Lampang Cancer Hospital

Hospital-based Cancer Registration Publications:

- Hospital Based Cancer Registry, LPCH 1999 (Published April 2002)
- Hospital Based Cancer Registry, LPCH 2001 (Published June 2002)
- Hospital Based Cancer Registry, LPCH 2002 (Published April 2003)
- Hospital Based Cancer Registry, LPCH 2003 (Published June 2004)
- Hospital Based Cancer Registry, LPCH 2004 (Published June 2005)
- Hospital Based Cancer Registry, LPCH 2005 (Published June 2006)
- Hospital Based Cancer Registry, LPCH 2006 (Published March 2007)
- Hospital Based Cancer Registry, LPCH 2007 (Published July 2008)
- Hospital Based Cancer Registry, LPCH 2008 (Published August 2009)
- Hospital Based Cancer Registry, LPCH 2009 (Published August 2010)
- Hospital Based Cancer Registry, LPCH 2010 (Published August 2011)
- Hospital Based Cancer Registry, LPCH 2011 (Published March 2012)
- Hospital Based Cancer Registry, LPCH 2012 (Published March 2013)
- Hospital Based Cancer Registry, LPCH 2013 (Published February 2014)
- Hospital Based Cancer Registry, LPCH 2014 (Published June 2015)
- Hospital Based Cancer Registry, LPCH 2015 (Published June 2016)
- Hospital Based Cancer Registry, LPCH 2016 (Published June 2017)
- Hospital Based Cancer Registry, LPCH 2017 (Published June 2018)
- Hospital Based Cancer Registry, LPCH 2018 (Published June 2019)
- Hospital Based Cancer Registry, LPCH 2019 (Published May 2020)
- Hospital Based Cancer Registry, LPCH 2020 (Published May 2021)
- Hospital Based Cancer Registry, LPCH 2021 (Published June 2022)
- Hospital Based Cancer Registry, LPCH 2022 (Published May 2023)

Population- based Cancer Registration Publications:

- Cancer Incidence in Lampang Vol. II, 1993-1997 (Published January 2002)
- Cancer Mortality in Lampang, 1990-2000 (Published August 2003)
- Cancer Incidence and Mortality in Lampang Vol. III, 1998-2002 (Published July 2004)
- Cancer Survival in Lampang, 1990-2002 (Published November 2005)
- Cancer Incidence in Lamphun, 1998-2002 (Published May 2006)
- Cancer Incidence in Phitsanulok, 1998-2002 (Published September 2006)
- Trends in Cancer Incidence in Lampang, Thailand, 1985-2004 (Published October 2007)
- Cancer Incidence in Northern, Thailand, 2003-2007 (Published October 2009)
- Cancer incidence in Phare, Thailand, 2007-2009 (Published August 2011)
- Trend cancer survival in Lampang, Thailand, 1988-2007 (Published September 2012)
- Cancer incidence in Chiang Rai, Thailand, 2008-2010 (Published October 2013)
- Cancer Incidence in Northern, Thailand, 2008-2012 (Published October 2014)
- Cancer Incidence Trend in Lampang, Thailand, 1988-2012 (Published November 2014)
- Cancer Incidence Trend in Phayao, Thailand, 2010-2012 (Published September 2015)
- Cancer Incidence Trend in Northern Thailand, 1993-2012 (Published December 2015)
- Cancer Survival in Northern Thailand, 2003-2012 (Published August 2016)
- Epidemiology of Liver Cancer in North Thailand (Published September 2017)
- Trends In Cancer Incidence and Mortality in Northern Thailand, 1993-2017 (Published February 2020)
- Cancer epidemiology of an aging population in Upper-Northern Thailand from 2013 to 2017 (Journal of Medicine and Health Sciences Published Vol.28 No.2 August 2021)
- Incidence and Mortality Rates of Cancer in Mae Hong Son Province. (Srinagarind Medical Journal Published Vol.38 No.1 January - February 2023)

Cancer in Thailand Publications:

- Cancer in Thailand vol. II, 1992-1994 (Published 1999)
- Cancer in Thailand vol. III, 1995-1997 (Published 2003)
- Cancer in Thailand vol. IV, 1998-2000 (Published 2007)
- Cancer in Thailand vol. V, 2001-2003 (Published 2009)
- Cancer in Thailand vol. VI, 2004-2006 (Published 2012)
- Cancer in Thailand vol. VII, 2007-2009 (Published 2013)
- Cancer in Thailand vol. VIII, 2010-2012 (Published 2015)
- Cancer in Thailand vol. IX, 2013-2015 (Published 2018)
- Cancer in Thailand vol. X, 2016-2018 (Published 2021)

International Publications:

- Cancer in Five Continents Vol. VIII, 1993-1997 IARC, WHO. Scientific Publications No. 155 (Published 2002)
- Cancer in Five Continents Vol. IX, 1998-2002 IARC, WHO Scientific Publications No. 160 (Published 2007)
- Cancer in Five Continents Vol. X, 2003-2007 IARC, WHO Scientific Publications No. 164 (Published 2013)
- Cancer Survival in Africa, Asia, the Caribbean and Central America, IARC, WHO Scientific Publications No. 162 (Published 2011)
- Lalitwongsa S, Pongnikorn D, Daoprasert K, Sriplung H, Bilheem S. Breast Cancer in Lampang, a Province in Northern Thailand: Analysis of 1993-2012 Incidence Data and Future Trends. *Asian Pac J Cancer Prev*. 2015;16(18):8327-33.
- Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang X-S, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet*. 2015 Mar 14;385(9972):977-1010.
- Pruksakorn D, Phanphaisarn A, Pongnikorn D, Daoprasert K, Teeyakasem P, Chaiyawat P, et al. AgeStandardized Incidence Rates and Survival of Osteosarcoma in Northern Thailand. *Asian Pac J Cancer Prev*. 2016;17(7):3455-8.
- Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M, CONCORD working group, et al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). *Gynecol Oncol*. 2017 Feb;144(2):405-13.
- Matz M, Coleman MP, Carreira H, Salmerón D, Chirlaque MD, Allemani C, CONCORD working group, et al. Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). *Gynecol Oncol*. 2017 Feb;144(2):396-404.
- Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001-10: a population-based registry study. *Lancet Oncol*. 2017 Jun;18(6):719-31.
- Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, CONCORD working group, et al. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89,828 children from 198 registries in 53 countries. *Lancet Haematol*. 2017;4(5):e202-17.
- Virani S, Bilheem S, Chansaard W, Chitapanarux I, Daoprasert K, Khuanchana S, et al. National and Subnational Population-Based Incidence of Cancer in Thailand: Assessing Cancers with the Highest Burdens. *Cancers*. 2017;9.

- Sripan P, Sriplung H, Pongnikorn D, Virani S, Bilheem S, Chaisaengkhaum U, et al. Trends in Female Breast Cancer by Age Group in the Chiang Mai Population. *Asian Pac J Cancer Prev*. 2017 01;18(5):1411–6.
- Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, CONCORD working group, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet*. 2018 Jan 30;
- Pongnikorn D, Daoprasert K, Waisri N, Laversanne M, Bray F. Cancer incidence in northern Thailand: Results from six population-based cancer registries 1993-2012. *Int J Cancer*. 2018 May 1;142(9):1767–75.
- Claudia Allemani, Tomohiro Matsuda, Veronica Di Carlo, Rhea Harewood, Melissa Matz, Maja Nikšić, Audrey Bonaventure, Mikhail Valkov, Christopher J Johnson, Jacques Estève, Olufemi J Ogunbiyi, Gulnar Azevedo e Silva, Wan-Qing Chen, Sultan Eser, Gerda Engholm, Charles A Stiller, Alain Monnereau, Ryan R Woods, Otto Visser, Gek Hsiang Lim, Joanne Aitken, Hannah K Weir, Michel P Coleman, CONCORD Working Group* .Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. www.thelancet.com Published online January 30, 2018
- Joanne T. Chang, Jihyoun Jeon, Hutcha Sriplung, Seesai Yeesoonsang, Surichai Bilheem, Laura Rozek, Imjai Chitapanarux, Donsuk Pongnikorn, Karnchana Daoprasert, Patravoot Vatanasapt, Krittika Suwanrungruang, Rafael Meza. Temporal Trends and Geographic Patterns of Lung Cancer Incidence by Histology in Thailand, 1990 to 2014. *American Society of Clinical Oncology*, 2018
- Ilona Argirion, Katie R Zarins, Kali Defever, Krittika Suwanrungruang, Joanne T Chang, Donsuk Pongnikorn, Imjai Chitapanarux, Hutcha Sriplung, Patravoot Vatanasapt, Laura S Rozek. Temporal Changes in Head and Neck Cancer Incidence in Thailand Suggest Changing Oropharyngeal Epidemiology in the Region. *Journal of global oncology*. 2019;5.
- Serena S Bidwell, Catherine C Peterson, Kathryn Demanelis, Katie R Zarins, Rafael Meza, Hutcha Sriplung, Surapon Wiangnon, Thirachit Chotsampancharoen, Imjai Chitapanarux, Donsuk Pongnikorn, Karnchana Daoprasert, Krittika Suwanrungruang, Wasan Chansaard, Laura S Rozek. Childhood cancer incidence and survival in Thailand: A comprehensive population-based registry analysis, 1990-2011. *Pediatric blood & cancer*. 2019;66(1).

- Donlapark Ponnoprat, Papangkorn Inkeaw, Jeerayut Chaijaruwanich, Patrinee Traisathit, Patumrat Sripan, Nakarin Inmutto, Wittanee Na Chiangmai, Donsuk Pongnikorn, Imjai Chitapanarux. Classification of hepatocellular carcinoma and intrahepatic cholangiocarcinoma based on multi-phase CT scans. *Medical & biological engineering & computing*. 2020;58(10).
- Donsuk Pongnikorn, Phichayut Phinyo, Jayanton Patumanond, Karnchana Daoprasert, Pachaya Phothong, Boonying Siribumrungwong. Individualized Prediction of Breast Cancer Survival Using Flexible Parametric Survival Modeling: Analysis of a Hospital-Based National Clinical Cancer Registry. *Cancers*. 2021;13(7).
- Jeerawan Klangjorhor, Donsuk Pongnikorn, Areerak Phanphaisarn, Parunya Chaiyawat, Pimpisa Teeyakasem, Pathacha Suksakit, Arnat Pasena, Sasimol Udomruk, Santhasiri Orrapin, Samatit Pornwattanavate, Narate Waisri, Karnchana Daoprasert, Taweechok Wisanuyotin, Chalongpon Santong, Suleeporn Sangrajang, et al. An analysis of the incidence and survival rates of bone sarcoma patients in thailand: reports from population-based cancer registries 2001–2015. *Cancer Epidemiology*. 2022;76.
- Maláková K, Cabasag CJ, Bardot A, Sangrajang S, Chitapanarux I, Sripan P, et al. Cancer survival in Thailand from 1997 to 2012: Assessing the impact of universal health coverage. *J Cancer Policy*. 2022;34:100353.
- Sripan P, Rerkasem A, Pongnikorn D, Chitapanarux I, Tangmunkongvorakul A, Ukranun W, et al. Trends in the Incidence of Kaposi's Sarcoma and Non-Hodgkin Lymphoma in Northern Thailand during the Time Period of Universal Access to Antiretroviral Treatment, 1998-2017. *Asian Pac J Cancer Prev*. 2023;24(3):1055-61.
- Soerjomataram I, Cabasag C, Bardot A, Fidler-Benaoudia MM, Miranda-Filho A, Ferlay J, et al. Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries. *Lancet Oncol*. 2023;24(1):22-32.

Cite

Cancer Registry Unit, Lampung Cancer Hospital. Hospital Based Cancer Registry, Lampung Cancer Hospital 2023. Lampung: Lampung Cancer Hospital, 2024.

สถิติโรคมะเร็ง โรงพยาบาลมะเร็งลำปาง ปี พ.ศ. 2566

(Hospital-Based Cancer Registry
Annual Report 2023)

Publisher

Lampang Cancer Hospital, Department of Medical Services,
Ministry of Public Health
199, Village 12, Pichai Sub-district, Muang district, Lampang, 52000